Nasvax Revenue

Biotechnology Research • Nes Ziona, Center District, Israel • 1-10 Employees

Nasvax revenue & valuation

Annual revenue	$10,000,000
Revenue per employee	$2,000,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$32,000,000
Total funding	No funding

Key Contact at Nasvax

Erez Chimovits

CEO

Company overview

Headquarters	18 Einstien St. Kiryat Weizmann, Science Park, P.O.B 4122, Ness Zionna, 74140, IL
Website	nasvax.com
Keywords	Vaccines & Immunotherapeutic Products
Founded	2004
Employees	1-10
Socials

About Nasvax

NasVax develops improved vaccines and immunotherapeutic products. The company has four distinct product areas: i. oral anti-CD3 monoclonal antibody immunotherapeutic; ii. VaxiSome® technology, which is an adjuvant-delivery system for enhancing the immunogenicity of vaccines and immunotherapeutics; iii. group-common pneumococcal vaccine, which is a protein-based vaccine that could become the field’s third-generation product; and iv. BBS1-based immunotherapeutics for Alzheimer’s disease.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

C-Suite

Employees by Department

Nasvax has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

Nasvax has never raised funding before.

Frequently asked questions

Nasvax is located in Nes Ziona, Center District, IL.

Nasvax generates an estimated annual revenue of $10,000,000. This revenue figure reflects the company's market position and business performance in its industry.

Nasvax has an estimated valuation of $32,000,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Nasvax was founded in 2004, making it 22 years old. The company has established itself as a significant player in its industry over this time.

Nasvax has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at Nasvax

Erez Chimovits

CEO

4.8

40,000 users